{
    "clinical_study": {
        "@rank": "114442", 
        "arm_group": [
            {
                "arm_group_label": "Carbatin", 
                "arm_group_type": "Experimental", 
                "description": "Carbatin is initiated at 100 mg at night and slowly titrated to 300~800 mg three times/day over 4 to 25 days"
            }, 
            {
                "arm_group_label": "Neurontin", 
                "arm_group_type": "Active Comparator", 
                "description": "Neurontin is initiated at 100 mg at night and slowly titrated to 300~800 mg three times/day over 4 to 25 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the efficacy of Gabapentin (Carbatin & Neurontin) in\n      patients with neuropathy pain."
        }, 
        "brief_title": "Clinical Study for Assessment of the Efficacy of Gabapentin (Carbatin and Neurontin) in Patients With Neuropathy Pain", 
        "completion_date": {
            "#text": "September 2011", 
            "@type": "Actual"
        }, 
        "condition": [
            "Neuropathy", 
            "Pain"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who have been diagnosed the disease of neuropathy pain arising from diabetic\n             peripheral neuropathy, postherpetic neuralgia, traumatic/surgical nerve injury,\n             incomplete spinal cord injury, or trigeminal neuralgia and if they have a mean weekly\n             pain score of at least 4 on the 100-mm visual analog scale (VAS) of the Short-Form\n             McGill Pain Questionnaire (SF-MPQ) completed a screening / baseline period before\n             randomization. Additional disease-specific inclusion criteria are listed in Table 1.\n\n          -  Subjects must be 20 years of age or older.\n\n        Exclusion Criteria:\n\n          -  Subjects who are pregnant, lactating or of childbearing potential not using effective\n             contraceptives.\n\n          -  Subjects who have a clinically significant or unstable medical or psychiatric\n             condition.\n\n          -  Subjects who are known of hypersensitivity to Gabapentin.\n\n          -  Serum creatinine > 1.5 times the upper limit of normal\n\n          -  Subjects who have received nerve blocks or acupuncture for pain relief within four\n             weeks before a screening / baseline period.\n\n          -  Subjects who have the presence of chronic pain other than the target pain being\n             studied (unless the chronic pain is in a different body region than the target pain\n             and its intensity is not greater than that of the target pain).\n\n          -  Subjects who have received nondrug therapies or any special procedures for the relief\n             of the target pain within two weeks before a baseline visit.\n\n          -  Subjects who are using the following agents within 30 days prior to screening:\n             antidepressants, opioids, other anticonvulsants, local anaesthetic injections or any\n             investigational drug."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02074267", 
            "org_study_id": "S08174"
        }, 
        "intervention": [
            {
                "arm_group_label": "Carbatin", 
                "description": "Carbatin\u00ae or Neurontin\u00ae is initiated at 100 mg at night and slowly titrated to 300~800 mg three times/day over 4 to 25 days.\nThe dose of Carbatin\u00ae or Neurontin\u00ae taken by each patient will amount to 100 to 2400 mg /day oral if the pain intensity reaches a VAS score \u22674. The maintenance dose of Carbatin\u00ae or Neurontin\u00ae will throughout for at least 14 days of the treatment period.", 
                "intervention_name": "Carbatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Neurontin", 
                "description": "Carbatin\u00ae or Neurontin\u00ae is initiated at 100 mg at night and slowly titrated to 300~800 mg three times/day over 4 to 25 days.\nThe dose of Carbatin\u00ae or Neurontin\u00ae taken by each patient will amount to 100 to 2400 mg /day oral if the pain intensity reaches a VAS score \u22674. The maintenance dose of Carbatin\u00ae or Neurontin\u00ae will throughout for at least 14 days of the treatment period.", 
                "intervention_name": "Neurontin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Gabapentin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 26, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tainan", 
                    "country": "Taiwan", 
                    "zip": "712"
                }, 
                "name": "Nang Kuang Pharmaceutical Co., LTD"
            }
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Taiwan: Institutional Review Board"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Evaluation of pain intensity using the visual analog scale (VAS)", 
            "safety_issue": "No", 
            "time_frame": "up to six weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02074267"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Nang Kuang Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "collaborator": {
                "agency": "Taichung Veterans General Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Nang Kuang Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2009", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}